Flaveome Biopharmaceuticals' lead drug candidate is a proteasome inhibitor that also inhibits PI3K/Akt/mTOR signalling. Other drug candidates in the company's pipeline include AMPK activators.
Flaveome's drug candidates have demonstrated selective targeting towards cancer cells without significantly affecting normal cells. This is one of the features contributing to their improved safety profile and distinguishes these compounds from most of the currently available cancer chemotherapeutic agents.
The company has unique access to a rationally-designed library of novel small molecules derived from flavonoid structures. Flavonoids occur naturally in fruits, vegetables, and beverages, such as tea, coffee, beer and wine. Flavonoids have been demonstrated to have many potentially beneficial effects on human health.
Thank you for visiting. We hope to launch the company's website in 2012. |
